To evaluate the value of multiparametric magnetic resonance imaging (mpMRI) in the detection of significant prostate cancer (PCa) and to compare transperineal MRI/ ultrasonography fusion biopsy (fusPbx) with conventional transrectal systematic biopsy (sysPbx) in biopsy-na€ ıve patients.
Objectives
To evaluate the value of multiparametric magnetic resonance imaging (mpMRI) in the detection of significant prostate cancer (PCa) and to compare transperineal MRI/ ultrasonography fusion biopsy (fusPbx) with conventional transrectal systematic biopsy (sysPbx) in biopsy-na€ ıve patients.
Patients and Methods
This multicentre, prospective trial investigated biopsy-na€ ıve patients with suspicion of PCa undergoing transperineal fusPbx in combination with transrectal sysPbx (comPbx). The primary outcome was the detection of significant PCa, defined as Gleason pattern 4 or 5. We analysed the results after a study period of 2 years.
Results
The study included 214 patients. The median (range) number of targeted and systematic cores was 6 (2-15) and 12 (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) , respectively. The overall PCa detection rate of comPbx was 52%. FusPbx detected more PCa than sysPbx (47% vs 43%; P = 0.15). The detection rate of significant PCa was 38% for fusPbx and 35% for sysPbx (P = 0.296). The rate of missed significant PCa was 14% in fusPbx and 21% in sysPbx. ComPbx detected significantly more significant PCa than fusPbx and sysPbx alone (44% vs 38% vs 35%; P < 0.005). In patients presenting with Prostate Imaging Reporting and Data System (PI-RADS) 4 and 5 lesions there was a higher detection rate of significant PCa than in patients presenting with PI-RADS ≤3 lesions in comPbx (61% vs 14%; P < 0.005).
Introduction
In the last decade, multiparametric MRI (mpMRI) of the prostate has become an important tool in prostate cancer (PCa) diagnostics, enabling better tumour visualization and targeting [1, 2] . The Prostate Imaging Reporting and Data System (PI-RADS), which was introduced in 2012 and updated in 2015, provides a framework for standardized reporting of mpMRI findings [3, 4] . It has been shown that the lesion-assigned PI-RADS score is associated with tumour detection rates and aggressiveness [5] [6] [7] .
Targeted biopsy can be performed as in-bore MRI-targeted biopsy, cognitive fusion or software-assisted MRI/ ultrasonography fusion biopsy (fusPbx) [2, 8, 9] . Earlier studies performed in patients with previous negative biopsies showed that mpMRI combined with targeted biopsy is a promising method for PCa detection [10] [11] [12] . Moreover, it has been shown that targeted biopsy detects significantly more highrisk PCa, whereas the detection rate of low-risk PCa is lower [13] . Consequently, most of the present guidelines recommend mpMRI and consecutive targeted biopsy in patients where suspicion of PCa remains after a negative biopsy [14, 15] .
The use of mpMRI and targeted biopsy in biopsy-na€ ıve patients is controversial. In a recently published landmark study, the sensitivity of mpMRI alone was shown to be clearly superior to that of conventional biopsy in biopsy-na€ ıve men [16] ; however, fusion biopsy was not assessed. Instead, transperineal mapping biopsy cores harbouring PCa were correlated to the mpMRI without the use of a targeted biopsy method [16] . Previous studies have suggested a benefit of fusPbx in biopsy-na€ ıve patients in terms of higher detection rates for significant PCa [17] [18] [19] [20] . Currently, a randomized, multicentre trial for MRI-targeted biopsy in comparison with conventional biopsy is on-going (PRECISION trial NCT02380027).
When the present study was initiated in 2015, TRUS-guided prostate biopsy was included as the standard method for diagnosing PCa in patients without prior prostate biopsy, reflecting the clinical routine. To the best of our knowledge, this is the first multicentre study comparing transperineal fusPbx with transrectal systematic biopsy (sysPbx). The aim of the study was to evaluate the value of mpMRI by comparing targeted transperineal fusPbx with both transrectal sysPbx and the combination of both biopsy techniques (comPbx) in biopsy-na€ ıve patients in a multicentre setting.
Patients and Methods

Recruitment
In this prospective, multicentre diagnostic study, biopsy-na€ ıve patients (aged >40 and ≤75 years) with elevated PSA levels (>3.0 and ≤50.0 ng/mL) and/or abnormal DRE were enrolled consecutively (German Clinical Trials Registry No. DRKS00005986). Patients with prior negative prostate biopsy, known PCa or contraindications for mpMRI were excluded.
Patients from two study sites in Germany (Department of Urology, University of Dresden and Department of Urology, University of Heidelberg) were included. The study was approved by the institutional review boards of the Universities of Dresden and Heidelberg (EK31012015 and S-652/2013).
At both study sites, FusPbx was routinely performed via the transperineal approach and combined with transrectal (Dresden study site) or transperineal sysPbx (Heidelberg study site). When the present study was initiated in 2015, conventional TRUS-guided prostate biopsy was included as the standard method for diagnosing PCa in patients without prior prostate biopsy because this approach is the most representative of common clinical practice; therefore, all patients underwent transperineal fusPbx combined with transrectal sysPbx. The primary endpoint was the proportion of patients diagnosed with significant PCa, defined as the presence of Gleason pattern 4 or 5 disease detected by at least one of the two biopsy methods. Secondary endpoints were the proportion of patients diagnosed with insignificant PCa, defined as Gleason score (GS) 6 and the proportion of patients diagnosed with significant PCa presenting lesions with PI-RADS scores ≥4. Furthermore, the overall cancer detection rates of fusPbx, sysPbx and comPbx were investigated. Next, the proportion of positive cores with any cancer (number of cores with cancer in relation to the number of cores taken) was studied. Finally, the number of patients in whom mpMRI showed definitive lesions (PI-RADS ≥4) but in whom biopsy presented no cancer or GS 6 disease were evaluated. We analysed the results after a study period of 2 years.
Investigations of Multiparametric MRI
Patients underwent mpMRI at the Department of Radiology of the University Hospital in Dresden, at the German Cancer Research Centre in Heidelberg, or in ambulatory radiology offices. At both study sites (Dresden and Heidelberg), all mpMRI of the prostate were performed on 3-Tesla systems (Siemens Medical Solutions, Erlangen, Germany) without the use of endorectal coils. mpMRI protocols included T2-weighted images in transverse and coronal orientation, T1-weighted images, diffusion-weighted images, dynamic contrast-enhanced imaging and contrastenhanced T1-weighted images with fat suppression in the transverse orientation. Total mpMRI acquisition time was 30 min.
The evaluation of mpMRI data was performed under supervision of uro-radiologists with >10 years' experience (Dresden and Heidelberg) in evaluating prostate mpMRI. PI-RADS v1 and v2 classifications [3, 4] were used to evaluate tumour-suspicious lesions. When mpMRI was performed in ambulatory radiology offices, tumour-suspicious lesions were marked 'in-house'.
For patients whose mpMRI was evaluated according to PI-RADS, all lesions detected in mpMRI were evaluated regarding tumour detection rate and GS. The maximum PI-RADS score in mpMRI was defined according to the lesion with the highest PI-RADS score of all lesions per patient. 
Prostate Biopsy
The BioJet-System (D&K Technologies, Barum, Germany) was used at the Dresden study site and the BiopSee-System (Medcom, Darmstadt, Germany) was used at the Heidelberg study site for transperineal fusPbx as described previously [21, 22] . Targeted biopsy was performed using a transperineal approach, while taking at least two cores per lesion, depending on the size of the lesion. Lesions with PI-RADS scores ≥2 were biopsied in a targeted fashion. Subsequently, every patient underwent a conventional sysPbx via the transrectal approach. In sysPbx, the needle was placed according to a standardized scheme covering 12 regions of the prostate (medial and lateral apex, medial and lateral mid prostate and medial and lateral base in both lobes). The sysPbx was completed by the same urologist who had performed the targeted biopsy.
All biopsy specimens were investigated at the Departments of Pathology at both study sites. The biopsy cores were paraffin embedded. Five step-sections were cut at 2-lm intervals and stained with haematoxylin and eosin for microscopic evaluation. A GS ≥7 (3 + 4) was defined as significant PCa.
Statistical Analysis
Data were analysed using SPSS v.23.0 (IBM Corp., Armonk, NY, USA). Categorial data are presented as absolute and relative frequencies. Continuous variables are described as means, complemented by medians and ranges. Student's t-test and the chi-squared test were applied to determine differences between numerical and categorial variables. The McNemar test was used to compare the detection rate of fusPbx with that of sysPbx and that of comPbx. P values <0.05 were taken to indicate statistical significance. Univariate and multivariate logistic regression analyses were used to evaluate the prediction of significant PCa in patients with reported PI-RADS scores.
Results
After a study period of 2 years, 242 screened patients had been enrolled. Table 2 ).
ComPbx detected significantly more PCa than fusPbx (52% vs 47%; P < 0.005) and sysPbx alone (52% vs 43%; P < 0.005).
More importantly, comPbx detected significantly more significant PCa than fusPbx (44% vs 38%; P < 0.005) and sysPbx alone (44% vs 35%; P < 0.005). FusPbx in addition to sysPbx resulted in a detection rate increase of 27% (20/74) for significant PCa and 41% (7/17) for insignificant PCa compared with sysPbx in all included patients. By contrast, additional sysPbx led to a 16% (13/81) increase in significant PCa and 21% (4/19) more PCa with a GS ≤6 than fusPbx alone.
Regarding the proportion of positive cores in patients with proven PCa, a mean (AESD) of 45 (AE30)% and 30 (AE27)% of cores taken by fusPbx and sysPbx showed evidence of any PCa (P < 0.005), respectively. Regarding the proportion of significant PCa in patients with evidence of PCa, a mean (AESD) of 37 (AE32)% and 22 (AE25)% of cores taken by fusPbx and sysPbx showed evidence of significant PCa (P < 0.005), respectively.
Evaluation of mpMRI and Detection of Significant PCa
In total, 380 lesions were detected on mpMRI. A total of 50 patients underwent mpMRI in ambulatory radiology offices. If lesions were not classified primarily according to PI-RADS, PI-RADS scores were not assigned in the later re-evaluation by in-house radiologists. Hence, mpMRI was evaluated according to PI-RADS scores in 170 patients. Altogether, 10% (n = 22), 18% (n = 39), 33% (n = 70) and 18% of patients (n = 39) presented a maximum PI-RADS score of 2, 3, 4 and 5, respectively. Considering only these patients (n = 170), the detection rate was 51% (n = 87) for any PCa and 39% (n = 66) for clinically significant PCa in comPbx. In patients with a maximum PI-RADS score ≥4 (n = 109), fusPbx detected 56% (n = 61) and sysPbx 50% (n = 55) of clinically significant PCa (P = 0.210). In this subgroup, additional fusPbx detected 20% (11/55) more clinically significant PCa than sysPbx alone, while additional sysPbx would have detected 8% (5/61) more significant PCa. The detection rates of clinically significant PCa in comPbx were 14% (n = 3), 13% (n = 5), 46% (n = 32) and 87% (n = 34) in patients with maximum PI-RADS scores of 2, 3, 4 and 5, respectively. Clinically significant PCa was missed by fusPbx in 33% (1/3), 40% (2/5), 13% (4/32) and 3% of patients (1/34) with maximum PI-RADS scores of 2, 3, 4 and 5, respectively. By contrast, sysPbx did not find significant PCa in 33% (1/3), 20% (1/5), 9% (3/32) and 24% (8/34) of patients with maximum PI-RADS scores of 2, 3, 4 and 5, respectively. In patients without an assigned PI-RADS score, sysPbx and fusPbx missed 33% (7/18) and 28% (5/18) of significant PCa, respectively. Figure 1 represents the overall cancer detection rate and the detected GS per lesion in patients with mpMRI evaluated according to PI-RADS.
In patients presenting with at least one lesion with a maximum PI-RADS score ≥4 there was a higher detection rate of clinically significant PCa than in patients presenting with a maximum PI-RADS score ≤3 in comPbx (61% [66/ 109] vs 14% [8/61]; P < 0.005). Similarly, fusPbx and sysPbx detected significantly more clinically significant PCa in patients with maximum PI-RADS scores ≥4 than in patients with maximum PI-RADS scores ≤3 (fusPbx: 56% [61/109] vs 8% [5/61], P < 0.001; sysPbx: 50% (55/109) vs 10% (6/61), P < 0.001). Table 3 shows univariate and multivariate analyses of the detection of significant PCa in patients with reported PI-RADS scores. The strongest independent predictors for the detection of significant PCa were an increased PSA and evidence of at least one lesion with a PI-RADS score ≥4. By contrast, the evidence of lesions with maximum PI-RADS scores of 3 was not independently predictive of a significant PCa.
In lesion-based analysis considering all PI-RADS lesions (n = 291), the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) for the detection of significant PCa in patients with at least one lesion classified as PI-RADS ≥ 4 were 83%, 63%, 47% and 90%, respectively. Regarding the localization of lesions harbouring PCa in all patients regardless of use of the PI-RADS (132 lesions in 100 patients), 52% (n = 68), 28% (n = 37) and 20% (n = 27) were located in the peripheral, transition and anterior zones of the prostate, respectively.
Discussion
The aim of the present prospective, multicentre study was to compare transperineal fusPbx with conventional transrectal sysPbx. The latter represented the standard method for diagnosing PCa in biopsy-na€ ıve patients when the study was initiated.
The study showed that transperineal fusPbx with a median of 6 cores tends to detect more significant PCa than transrectal 12-core sysPbx, but does not seem to be superior to sysPbx in biopsy-na€ ıve patients; however, the combination of both biopsy methods detects more clinically significant PCa than each method alone. As expected, in patients presenting with at least one tumour-suspicious lesion classified as PI-RADS 4 or 5 there was a higher detection rate of any and clinically significant PCa than in patients presenting with PI-RADS ≤3 lesions. In patients with maximum PI-RADS score ≥4, we were also unable to observe a significant difference in the detection of significant PCa for fusPbx compared with sysPbx.
To the best of our knowledge, this analysis represents the first prospective, multicentre study comparing transperineal, targeted fusPbx with transrectal sysPbx in biopsy-na€ ıve patients. Most of the published data concerning MRI-fusion biopsy in biopsy-na€ ıve patients have been derived from fusion platforms allowing both fusPbx and sysPbx via either a transrectal or a transperineal approach [8, 13, 23] . Fewer studies have reported a direct comparison of transperineal targeted with transperineal sysPbx [24, 25] . Porpiglia et al.
[26] investigated biopsy-na€ ıve patients randomized to groups receiving mpMRI or undergoing standard sysPbx. In the mpMRI group, patients received fusPbx, but if no lesion was detectable, patients underwent only sysPbx. In that study, fusPbx was performed either transperineally, in the case of lesions located in the transition, central or anterior zone, or transrectally, in the case of lesions situated in the peripheral zone (67.9% of lesions). Regardless of the approach used, the authors found fusPbx to be superior to sysPbx in the detection of any and clinically significant PCa [26] . In general, transperineal prostate biopsy carries a lower risk of infection than transrectal prostate biopsy [27, 28] . Additionally, targeted biopsy may reduce the infection rate as a result of the lower number of cores taken [29] . In a recent study comparing transrectal sysPbx with transperineal targeted biopsy, Huang et al. [30] reported a significantly lower infection rate in the transperineal cohort. In the present study, which focused on determining the benefit of fusPbx, sysPbx and comPbx, we therefore combined the standard transrectal with the transperineal approach. Consequently, infection rates could not be compared. As shown by other groups, however, infection rates can be minimized by choosing a transperineal approach for both targeted biopsy and sysPbx [24, 25] .
Recent data have supported the excellent performance of mpMRI before biopsy in improving the detection of high-risk cancer in men presenting for first biopsy. The results of a paired-cohort, blinded study evaluating the accuracy of mpMRI and transrectal biopsy as compared with template biopsy (the PROMIS study) revealed a high sensitivity (93%) and NPV (89%) for the detection of clinically significant cancer in mpMRI [16] . The authors concluded that mpMRI represents a triage test to identify patients who do not need a biopsy. MpMRI before biopsy would result in 27% fewer OR, odds ratio; PI-RADS, Prostate Imaging Reporting and Data System. Significant variables are shown in bold. Only patients with reported PI-RADS were included in this analysis (n = 170).
© 2017 The Authors BJU International © 2017 BJU International 57 performed biopsies, a 5% lower detection rate of insignificant PCa and an 18% increased detection rate of significant PCa [16] ; however, the PROMIS study did not evaluate fusiontargeted biopsy and its inherent targeting errors.
In the present study, we showed that mpMRI and consecutive targeted fusPbx in addition to sysPbx resulted in an even higher increase of 27% for significant PCa. However, we also demonstrated an increase of 41% for insignificant PCa compared with sysPbx alone in all patients. Considering patients with only PI-RADS 4 and 5 lesions in our cohort, additional fusPbx detected 20% more clinically significant PCa than sysPbx alone.
The notion that a negative mpMRI would be sufficient to completely omit prostate biopsy is challenged by the work of Pokorny et al. [20] . In their study, they described a reduction of 89% for low-risk PCa by targeted biopsy, while increasing the detection rate of intermediate-and high-risk PCa in 17% of cases; however, their study showed that sysPbx alone would still detect an important number of intermediate-and high-risk tumours (15 out of 108), either in the case of a negative mpMRI or one that was missed in targeted biopsy [20] . Filson et al. [31] also reported that significant cancer would be missed in up to 12% of cases if biopsies were not performed in patients for whom mpMRI showed no evidence of tumour-suspicious lesions. Moreover, in a retrospective study combining transrectal fusPbx with transrectal sysPbx, Mendhiratta et al. [32] showed that targeted biopsy significantly increased the detection rate for GS ≥7 PCa, whereas the overall cancer detection rates were similar in both types of biopsy. In line with the present study, targeted biopsy alone would still miss 17% of PCa with a GS ≥7. In the present cohort, the rate of missed clinically significant PCa in fusPbx was 14% in all patients and 16% in patients with a maximum PI-RADS score ≥4 and therefore similar to the current literature. Using the comPbx approach as the reference, the detection rates of significant PCa in comPbx were still 14% and 13% in patients presenting with maximum PI-RADS scores of 2 and 3, respectively. In contrast to these data, in the prospective controlled trial by Baco et al.
[17], biopsy-na€ ıve patients were randomized to fusPbx in combination with 12-core biopsy and to 12-core biopsy alone. In the fusPbx arm, only two cores per lesion were taken as targeted biopsy. The overall PCa detection rate and the detection rate of significant PCa were similar in the two study arms. Regarding only the two-core fusPbx, the detection rate of significant PCa was similar to that of the control arm. The authors therefore concluded that the systematic 12-core biopsy could be replaced by two-core fusPbx [17] . Because the combined approach resulted in significantly higher detection rates in the present study cohort, we do not favour fusPbx without sysPbx; however, because of the consistently high NPV of mpMRI in the PROMIS study and in the present cohort, the option not to proceed with immediate biopsy should be discussed in men with unsuspicious mpMRI [16] .
As mentioned above, the detection rate of significant PCa was not significantly higher in fusPbx alone than in sysPbx in all patients as well as in the subgroup including patients with maximum PI-RADS score ≥4. This may be attributed to the small sample size, the standardized protocol for sysPbx and an a priori higher detection rate in patients without prior biopsy. Furthermore, the present data indicate that there remained a high number of GS 6 tumours detected by fusPbx alone compared with sysPbx alone, which was also true for the subgroup of patients with maximum PI-RADS scores ≥4. This observation may be related to the relatively low specificity (63%) of PI-RADS ≥4 lesions for the detection of significant PCa. Nonetheless, the presence of PI-RADS ≥4 lesions is an independent predictor of the detection of significant PCa compared with maximum PI-RADS score ≤3 lesions. Previous studies reported that the suspicion level of lesions described in mpMRI was positively associated with the detection rate of significant PCa [11, 19, 33] . In the present cohort, lesion-based analysis showed that 8% of PI-RADS score 2 and 19% of PI-RADS score 3 lesions harboured clinically significant PCa. This detection rate is similar to rates reported in previous studies [5, 34] . Thus, in biopsyna€ ıve patients, prostate biopsy and targeting of PI-RADS score 3 lesions should be performed. In addition, it is still just as important to consider clinical factors such as PSA level and DRE results.
The median number of 18 cores taken with the combination of fusPbx and sysPbx is similar to that of a saturation biopsy, with 20-24 cores. Other studies described fusPbx in combination with volume-based systematic template biopsy with a median of 20-30 systematic cores, whereupon the detection rates of any and significant PCa were similar to the detection rates in the present study [35, 36] . A higher number of cores may result per se in a higher detection rate; however, 48% of PCa was detected by fusPbx in lesions localized in the transition and anterior zone of the prostate. Additional cores in fusPbx are therefore beneficial, because the biopsy is carried out in an image-based targeted manner and the demonstrated benefit cannot be attributed solely to the increased number of cores.
With regard to the implementation of prostate mpMRI in diagnosing PCa in biopsy-na€ ıve patients, economic aspects must be considered. Available resources are still inadequate for the use of mpMRI as the primary diagnostic tool for the detection of PCa in all patients [37] . Because of the insufficient number of facilities, prostate mpMRI is also confronted with logistical concerns [37] . Nevertheless, costeffectiveness for prostate mpMRI and image-guided biopsy strategies has been reported for patients with prior negative biopsy and biopsy-na€ ıve patients [38] [39] [40] . The present study has several limitations. We investigated a rather small number of biopsy-na€ ıve patients. We cannot exclude the possibility, therefore, that the difference in the detection rates in fusPbx compared with sysPbx would be higher with a higher number of patients included. Next, fusPbx and sysPbx were performed consecutively by the same urologist in a unblinded manner. Systematic cores were placed according to a predefined scheme. There was no additional software-based documentation that would allow retrospective analysis of systematic cores. Consequently, knowledge of the location of lesions in mpMRI could have influenced the operator in needle placement unwittingly during sysPbx. This could have resulted in a falsely high detection rate in sysPbx. Another limitation is that PI-RADS was not applied in all patients. Nevertheless, detection rates of any and clinically significant cancer in the subgroup analysis that included only patients with reported PI-RADS were similar to those obtained for the whole cohort. Our subgroup of patients with maximum PI-RADS score 2 and 3 lesions was rather small. This might limit the generalizability of the results from this subgroup. Another important point is that the two study sites used different systems for fusPbx, which might result in a bias. Both systems are rigid fusion systems with the option of elastic fusion if required. Nonetheless, differences in acquisition and tracking may cause systematic bias in both study centres. Detection rates for significant tumours, however, were not significantly different between study sites. We did not aim to compare the two fusion systems in this study; instead, the study reflects the daily practice using diverse fusion systems in different centres providing fusPbx. Lastly, we did not perform a standardized longterm follow-up assessment.
In conclusion, comPbx outperformed both fusPbx and sysPbx alone in the detection of overall PCa and significant PCa; therefore, biopsy-na€ ıve patients may benefit from mpMRI targeted fusPbx in combination with sysPbx.
